{"classes":[{"categories":[{"measurements":[{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG000","lowerLimit":"14.8","upperLimit":"NA","value":"31.8"},{"comment":"Follow-up duration too short relative to event accumulation to estimate upper limit.","groupId":"OG001","lowerLimit":"0.5","upperLimit":"NA","value":"12.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part F"}],"paramType":"MEDIAN","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 44 months","title":"Overall Survival (Parts E and F Only)","type":"SECONDARY","unitOfMeasure":"Months"}